Company news
Qiagen N.v. (NYSE:QGEN) news
Qiagen N.v. news releases on 6ix. Latest, Jul 22, 2025: QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels
Press releases — page 2
QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels
July 22, 2025
QIAGEN N.V. to Release Results for Q2 2025 and Hold Webcast
July 8, 2025
QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board
June 26, 2025
QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership
June 18, 2025
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
June 15, 2025
QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships
June 2, 2025
QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions
May 22, 2025
QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software
May 12, 2025
QIAGEN announces plans for transition in leadership of Supervisory Board
May 7, 2025
QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase
May 7, 2025
QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting
May 7, 2025
QIAGEN Expands Its Digital PCR Portfolio With New Lentivirus Solutions to Strengthen Cell and Gene Therapy Quality Control
April 29, 2025
QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025
April 22, 2025
QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation
April 15, 2025
QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast
April 8, 2025
QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook
April 6, 2025
QIAGEN Launches QIAprep& Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts
April 1, 2025
QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results
March 31, 2025
QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio
March 6, 2025
QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing
March 3, 2025